ProPhase Labs, Inc.
- Close
- Jul 2, 2026
- Market cap
- $1.12M
- 14.02M shares
- Filings
- 924
Q2 2026−35.8% FY25 yoy
Q2 2026N/M FY25 yoy
Q2 2026N/M FY25 yoy
FY 2025derivedN/M FY25 yoy
Q2 2026N/M FY25 yoy
Q2 2026−86.7% FY25 yoy
- $1.12M
- —
- 0.3×
- —
- —
- —
Twelve months to Jun 30, 2026 · derived
Price
Jul 2, 2026 · Official close
IEX last saleClose of record
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $4,345,000 | reported | |
| FY 2024 | 2024-12-31 | $6,770,000 | reported | |
| FY 2023 | 2023-12-31 | $34,984,000 revised | reported | |
| FY 2022 | 2022-12-31 | $122,647,000 | reported | |
| FY 2021 | 2021-12-31 | $79,042,000 | reported | |
| FY 2020 | 2020-12-31 | $14,514,000 | reported | |
| FY 2019 | 2019-12-31 | $9,876,000 | reported | |
| FY 2018 | 2018-12-31 | $13,126,000 | reported | |
| FY 2017 | 2017-12-31 | $9,867,000 | reported | |
| FY 2016 | 2016-12-31 | $4,206,000 revised | reported | |
| FY 2015 | 2015-12-31 | $2,518,000 revised | reported | |
| FY 2014 | 2014-12-31 | $22,070,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2024 | — | $0.00 | $0.00 | — | 41.88M sh | +132.1% | — |
| FY2023 | $0.00 | $588.00K | $588.00K | — | 18.05M sh | +5.0% | — |
| FY2022 | $9.35M | $2.15M | $11.51M | $0.30 | 17.18M sh | +11.0% | 46.7% |
| FY2021 | $4.55M | $917.00K | $5.46M | $0.30 | 15.49M sh | +2.2% | — |
| FY2019 | $5.82M | — | $5.82M | — | 11.58M sh | +0.2% | — |
Segments
LineFY2025ShareChange
Consumer products$4.35M100%−35.8%
Diagnostic Services$0.00——
Consumer Products———
Diagnostic Services———
Total$4.35M
Pharmaceutical preparations
ProPhase Labs, Inc. is the 189th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
ABEOAbeona Therapeutics Inc.$5.8M—1,223.1%$130.6MCNSYCerenome, Inc.$5.2M10.5%429.4%$5.7MENSCEnsysce Biosciences, Inc.$5.1M2.8%200.8%$7.6M
PRPHProPhase Labs, Inc. (this company)$4.3M35.8%339.3%$1.1M
CPHIChina Pharma Holdings, Inc.$4.1M8.5%76.9%$24.1MCRVOCervoMed Inc.$4.0M58.9%673.1%$27.6MMRKRMarker Therapeutics, Inc.$3.5M46.2%343.0%$15.0MCAMPCamp4 Therapeutics Corp$3.5M436.5%2,298.5%$254.8MTXMDTherapeuticsMD, Inc.$3.0M71.6%18.8%$20.9MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
ProPhase Labs, Inc. · CIK 868278 · Engraved from SEC EDGAR